S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.72
+0.02 (+2.18%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$0.68
$0.74
50-Day Range
$0.71
$2.29
52-Week Range
$0.65
$15.00
Volume
212,200 shs
Average Volume
555,702 shs
Market Capitalization
$2.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Soligenix MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Soligenix in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.55) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.03 out of 5 stars


SNGX stock logo

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Stock News Headlines

3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Why Are Soligenix Shares Trading Higher Today
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Soligenix Provides Regulatory Update on HyBryte™
Why Is Soligenix (SNGX) Stock Down 27% Today?
Why Is Soligenix (SNGX) Stock Down 35% Today?
Soligenix Announces Reverse Stock Split
See More Headlines
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings
11/12/2021
Today
5/29/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNGX
Employees
13
Year Founded
1987

Profitability

Net Income
$-13,800,000.00
Net Margins
-996.96%
Pretax Margin
-1,218.01%

Debt

Sales & Book Value

Annual Sales
$950,000.00
Book Value
($1.14) per share

Miscellaneous

Free Float
2,857,000
Market Cap
$2.16 million
Optionable
Not Optionable
Beta
1.74

Social Links


Key Executives

  • Christopher J. SchaberChristopher J. Schaber
    Chairman, President & Chief Executive Officer
  • Jonathan L. GuarinoJonathan L. Guarino
    Chief Financial Officer, Secretary & Senior VP
  • Oreola Donini
    Chief Scientific Officer & Senior Vice President
  • Richard C. Straube
    Chief Medical Officer & Senior Vice President
  • Adam T. Rumage
    VP-Regulatory Affairs & Project Management













SNGX Stock - Frequently Asked Questions

How have SNGX shares performed in 2023?

Soligenix's stock was trading at $0.4520 on January 1st, 2023. Since then, SNGX shares have increased by 60.4% and is now trading at $0.7250.
View the best growth stocks for 2023 here
.

Are investors shorting Soligenix?

Soligenix saw a increase in short interest in May. As of May 15th, there was short interest totaling 350,100 shares, an increase of 63.0% from the April 30th total of 214,800 shares. Based on an average daily trading volume, of 835,000 shares, the short-interest ratio is currently 0.4 days. Approximately 4.4% of the shares of the company are sold short.
View Soligenix's Short Interest
.

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our SNGX earnings forecast
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) issued its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The biopharmaceutical company earned $0.19 million during the quarter, compared to analyst estimates of $0.80 million. Soligenix had a negative trailing twelve-month return on equity of 589.84% and a negative net margin of 996.96%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by many different institutional and retail investors. Top institutional investors include First Wilshire Securities Management Inc. (0.78%) and Geode Capital Management LLC (0.73%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends
.

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.73.

How much money does Soligenix make?

Soligenix (NASDAQ:SNGX) has a market capitalization of $2.16 million and generates $950,000.00 in revenue each year.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -